CD20-Targeting Therapy Insights: Ofatumumab in Multiple Sclerosis Care

In episode 1, Bove explores how ofatumumab, a B-cell–depleting therapy, stands apart from fingolimod and fumarates, and why its mechanism may offer distinct treatment advantages.

Riley Bove, MD, an associate professor of neurology at UCSF, breaks down the ARTIOS phase 3b trial results, highlighting the exceptionally low relapse rates, MRI outcomes, and safety findings in patients switching therapies.

In this clip, a multiple sclerosis expert reflects on how ofatumumab’s role has expanded since FDA approval in 2020, from first-line use to special populations, and what this means for daily practice.

In this final episode, Riley Bove, MD, considers the next phase of MS research, emphasizing the need for innovative trial designs to address sequencing, discontinuation, and subgroup-specific treatment strategies.